Physicochemical properties determining drug detection in skin

Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be...

Full description

Saved in:
Bibliographic Details
Published inClinical and translational science Vol. 15; no. 3; pp. 761 - 770
Main Authors Bittremieux, Wout, Advani, Rohit S., Jarmusch, Alan K., Aguirre, Shaden, Lu, Aileen, Dorrestein, Pieter C., Tsunoda, Shirley M.
Format Journal Article
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.03.2022
John Wiley and Sons Inc
Wiley
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Chemicals, including some systemically administered xenobiotics and their biotransformations, can be detected noninvasively using skin swabs and untargeted metabolomics analysis. We sought to understand the principal drivers that determine whether a drug taken orally or systemically is likely to be observed on the epidermis by using a random forest classifier to predict which drugs would be detected on the skin. A variety of molecular descriptors describing calculated properties of drugs, such as measures of volume, electronegativity, bond energy, and electrotopology, were used to train the classifier. The mean area under the receiver operating characteristic curve was 0.71 for predicting drug detection on the epidermis, and the SHapley Additive exPlanations (SHAP) model interpretation technique was used to determine the most relevant molecular descriptors. Based on the analysis of 2561 US Food and Drug Administration (FDA)‐approved drugs, we predict that therapeutic drug classes, such as nervous system drugs, are more likely to be detected on the skin. Detecting drugs and other chemicals noninvasively on the skin using untargeted metabolomics could be a useful clinical advancement in therapeutic drug monitoring, adherence, and health status.
Bibliography:Wout Bittremieux and Rohit S. Advani contributed equally to this work.
Funding information
W.B. was supported by the Research Foundation – Flanders (12W0418N). This research was supported in part by the Intramural Research Program of National Institute of Environmental Health Sciences of the National Institutes of health (NIH; ES103363‐01).
ISSN:1752-8054
1752-8062
DOI:10.1111/cts.13198